In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies

The development of a drug-resistant cell line can take from 3 to 18 months. However, little is published on the methodology of this development process. This article will discuss key decisions to be made prior to starting resistant cell line development; the choice of parent cell line, dose of selecting agent, treatment interval, and optimizing the dose of drug for the parent cell line. Clinically relevant drug-resistant cell lines are developed by mimicking the conditions cancer patients experience during chemotherapy and cell lines display between two- and eight-fold resistance compared to their parental cell line. Doses of drug administered are low, and a pulsed treatment strategy is often used where the cells recover in drug-free media. High-level laboratory models are developed with the aim of understanding potential mechanisms of resistance to chemotherapy agents. Doses of drug are higher and escalated over time. It is common to have difficulty developing stable clinically relevant drug-resistant cell lines. A comparative selection strategy of multiple cell lines or multiple chemotherapeutic agents mitigates this risk and gives insight into which agents or type of cell line develops resistance easily. Successful selection strategies from our research are presented. Pulsed-selection produced platinum or taxane-resistant large cell lung cancer (H1299 and H460) and temozolomide-resistant melanoma (Malme-3M and HT144) cell lines. Continuous selection produced a lapatinib-resistant breast cancer cell line (HCC1954). Techniques for maintaining drug-resistant cell lines are outlined including; maintaining cells with chemotherapy, pulse treating with chemotherapy, or returning to master drug-resistant stocks. The heterogeneity of drug-resistant models produced from the same parent cell line with the same chemotherapy agent is explored with reference to P-glycoprotein. Heterogeneity in drug-resistant cell lines reflects the heterogeneity that can occur in clinical drug resistance.

[1]  A. Boddy,et al.  Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations , 2005, British Journal of Cancer.

[2]  F. Couch,et al.  Edinburgh Research Explorer Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma , 2022 .

[3]  R. Ozols,et al.  Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. , 1993, Cancer research.

[4]  K. Polyak,et al.  Tumor heterogeneity: causes and consequences. , 2010, Biochimica et biophysica acta.

[5]  F. Couch,et al.  Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers , 2008, Nature.

[6]  X. Yang,et al.  P-glycoprotein expression in ovarian cancer cell line following treatment with cisplatin. , 1995, Oncology research.

[7]  I. Wodinsky,et al.  Uptake and retention of daunomycin by mouse leukemic cells as factors in drug response. , 1968, Cancer research.

[8]  J. L. Biedler,et al.  Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. , 1970, Cancer research.

[9]  J. Filmus,et al.  Stability of c-K-ras amplification during progression in a patient with adenocarcinoma of the ovary. , 1985, Cancer research.

[10]  H. Pinedo,et al.  Pharmacokinetics of diammine(l,l cyclobutanedi carboxylato) platinum(II) (carboplatin) after intravenous administration , 1987 .

[11]  J. Trent,et al.  A cell line from a human ovarian carcinoma with amplification of the K-ras gene. , 1986, Cancer research.

[12]  T. Kawarabayashi,et al.  Establishment and characterization of a serous papillary adenocarcinoma cell line of the human ovary in a serum-free culture. , 1999, Pathology, research and practice.

[13]  L. Law.  Resistance in Leukemic Cells to a Guanine Analog, 8-Azaguanine , 1951, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[14]  H. Wheeler,et al.  Drug resistance mechanisms and MRP expression in response to epirubicin treatment in a human leukaemia cell line. , 1995, Leukemia research.

[15]  B. Stordal,et al.  Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells , 2006, Cancer Chemotherapy and Pharmacology.

[16]  Balázs Győrffy,et al.  Parallel Evolution under Chemotherapy Pressure in 29 Breast Cancer Cell Lines Results in Dissimilar Mechanisms of Resistance , 2012, PloS one.

[17]  L. Kèlland,et al.  Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. , 1989, British Journal of Cancer.

[18]  J. Buckner,et al.  Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  G. Mills,et al.  DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance. , 2011, Neoplasia.

[20]  I. Pastan,et al.  Characterisation of high-level cisplatin-resistant cell lines established from a human hepatoma cell line and human KB adenocarcinoma cells: cross-resistance and protein changes. , 1995, British Journal of Cancer.

[21]  L. de Leij,et al.  Characterization of three small cell lung cancer cell lines established from one patient during longitudinal follow-up. , 1988, Cancer research.

[22]  H. Parekh,et al.  Cross-resistance and collateral sensitivity to natural product drugs in cisplatin-sensitive and -resistant rat lymphoma and human ovarian carcinoma cells , 2009, Cancer Chemotherapy and Pharmacology.

[23]  K. Kiura,et al.  Characterization of non-small-cell lung cancer cell lines established before and after chemotherapy. , 2002, Lung cancer.

[24]  J. Trent,et al.  Tumor progression studied by analysis of cellular features of serial ascitic ovarian carcinoma tumors. , 1983, Cancer research.

[25]  M. Duffy,et al.  Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib , 2010, Molecular Cancer Therapeutics.

[26]  A. Nomeir,et al.  High-performance liquid chromatographic determination and stability of 5-(3-methyltriazen-1-yl)-imidazo-4-carboximide, the biologically active product of the antitumor agent temozolomide, in human plasma. , 1997, Journal of chromatography. B, Biomedical sciences and applications.

[27]  H. Meden,et al.  Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with plantinum. , 1997, European journal of cancer.

[28]  M. Clynes,et al.  Development of taxane resistance in a panel of human lung cancer cell lines. , 2008, Toxicology in vitro : an international journal published in association with BIBRA.

[29]  J. Burchenal,et al.  The induction of resistance to 4-amino-N10-methylpteroylglutamic acid in a strain of transmitted mouse leukemia. , 1950, Science.

[30]  C. Choi,et al.  Concentration-dependent collateral sensitivity of cisplatin-resistant gastric cancer cell sublines. , 2005, Biochemical and biophysical research communications.

[31]  Y. Li,et al.  Bridge linkage role played by CD98hc of anti-tumor drug resistance and cancer metastasis on cisplatin-resistant ovarian cancer cells , 2007, Cancer biology & therapy.

[32]  K. Kimura,et al.  Clinical Pharmacokinetics of Carboplatin , 1988, Journal of clinical pharmacology.

[33]  K. O'Byrne,et al.  Generation and Characterisation of Cisplatin-Resistant Non-Small Cell Lung Cancer Cell Lines Displaying a Stem-Like Signature , 2013, PloS one.

[34]  Betsy Paul,et al.  Lapatinib: a dual tyrosine kinase inhibitor for metastatic breast cancer. , 2008, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[35]  J. Haveman,et al.  Clonogenic assay of cells in vitro , 2006, Nature Protocols.

[36]  M. Tanioka,et al.  A Phase I, dose‐finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors *,† , 2012, Cancer science.

[37]  M. Gottesman,et al.  Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistant cancer cell lines. , 2003, Cancer research.

[38]  E. Moran,et al.  Multiple drug-resistance in variant of a human non-small cell lung carcinoma cell line, DLKP-A , 2004, Cytotechnology.

[39]  Sharon Peplinski,et al.  X-Linked Inhibitor of Apoptosis Protein Inhibits Apoptosis in Inflammatory Breast Cancer Cells with Acquired Resistance to an ErbB1/2 Tyrosine Kinase Inhibitor , 2010, Molecular Cancer Therapeutics.

[40]  Wellbutrin,et al.  Prescribing Information , 2015, European journal of haematology.

[41]  M. Westerfield,et al.  Characterization of paired tumor and non‐tumor cell lines established from patients with breast cancer , 1998, International journal of cancer.

[42]  J. Thompson,et al.  Resistance to ErbB2 Tyrosine Kinase Inhibitors in Breast Cancer Is Mediated by Calcium-Dependent Activation of RelA , 2010, Molecular Cancer Therapeutics.

[43]  M. Davey,et al.  Verapamil-stimulated glutathione transport by the multidrug resistance-associated protein (MRP1) in leukaemia cells. , 2001, Biochemical pharmacology.

[44]  P. Hegde,et al.  A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[45]  I. Pastan,et al.  Isolation and genetic characterization of human KB cell lines resistant to multiple drugs , 1985, Somatic cell and molecular genetics.

[46]  Joel Greshock,et al.  Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. , 2009, Cancer research.

[47]  Suzanne F. Jones,et al.  Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  N. Ragni,et al.  Establishment and characterization of three new cell lines derived from the ascites of human ovarian carcinomas. , 1996, Gynecologic oncology.

[49]  M. Ruevekamp,et al.  Cellular pharmacokinetics of carboplatin and cisplatin in relation to their cytotoxic action. , 1991, Biochemical pharmacology.

[50]  S. Hilsenbeck,et al.  Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers -- role of estrogen receptor and HER2 reactivation , 2011, Breast Cancer Research.

[51]  R. Kunzmann,et al.  Karyotype alterations in human ovarian carcinoma cells during long-term cultivation and nude mouse passage. , 1987, Cancer genetics and cytogenetics.

[52]  R. Bruno,et al.  Pharmacokinetics and metabolism of Taxotere (docetaxel). , 1993, Cancer surveys.

[53]  Z. Siddik,et al.  Distinct P‐glycoprotein expression in two subclones simultaneously selected from a human colon carcinoma cell line by cis‐diamminedichloroplatinum (II) , 1993, International journal of cancer.

[54]  M. Gottesman,et al.  Resistance to Paclitaxel in a Cisplatin-Resistant Ovarian Cancer Cell Line Is Mediated by P-Glycoprotein , 2012, PloS one.

[55]  A. Monks,et al.  Metallothionein gene expression and resistance to cisplatin in human ovarian cancer , 1990, International journal of cancer.

[56]  J. Whang‐Peng,et al.  Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. , 1983, Cancer research.

[57]  K. Mross,et al.  The pharmacokinetics of a 1-h paclitaxel infusion , 2000, Cancer Chemotherapy and Pharmacology.

[58]  M. Gore,et al.  Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin. , 1987, European journal of cancer & clinical oncology.

[59]  J. Kolesar,et al.  Clinical significance of ABCB1 genotyping in oncology , 2010, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[60]  Hong Ma,et al.  Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways , 2002, Oncogene.

[61]  I. Quirt,et al.  Temozolomide for the treatment of metastatic melanoma: a systematic review. , 2007, The oncologist.

[62]  H. Pinedo,et al.  Pharmacokinetics of carboplatin after i.v. administration. , 1987, Cancer treatment reports.

[63]  Thomas J. Hardcastle,et al.  Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma , 2010, Oncogene.

[64]  Tian-Li Wang,et al.  Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations. , 2005, Cancer research.

[65]  D. Schadendorf,et al.  Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  G. Peters,et al.  Similar chromosomal changes in cisplatin and oxaliplatin‐resistant sublines of the H69 SCLC cell line are not associated with platinum resistance , 2006, Genes, chromosomes & cancer.

[67]  T. Hall,et al.  Studies on folic reductase. II. Enzyme activity of embryonic organs of the chicken, rat, and human. , 1965, Cancer research.

[68]  R. Ueda,et al.  Chemosensitivity and radiosensitivity of small cell lung cancer cell lines studied by a newly developed 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) hybrid assay. , 1989, Cancer research.

[69]  W. H. Kim,et al.  Establishment and characterization of human ovarian carcinoma cell lines. , 1997, Gynecologic oncology.

[70]  E Wiltshaw,et al.  Carboplatin dosage: prospective evaluation of a simple formula based on renal function. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  M. Davey,et al.  Modulation of drug and radiation resistance in small cell lung cancer cells by paclitaxel , 2003, Anti-cancer drugs.

[72]  B. Stordal,et al.  Understanding cisplatin resistance using cellular models , 2007, IUBMB life.

[73]  G. Mills,et al.  Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition , 2011, Oncogene.

[74]  M. Davey,et al.  Altered drug sensitivity in response to idarubicin treatment in K562 human leukaemia cells , 1999, British journal of haematology.

[75]  M. Goldenberg.  Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. , 1999, Clinical therapeutics.

[76]  T. F. Patton,et al.  Clinical kinetics of intact cisplatin and some related species , 1981 .

[77]  H. Friedman,et al.  Temozolomide and treatment of malignant glioma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[78]  H. Pinedo,et al.  Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin. , 1984, Cancer treatment reports.

[79]  J. Smyth,et al.  Characterization and properties of nine human ovarian adenocarcinoma cell lines. , 1988, Cancer research.

[80]  M. Clynes,et al.  Acid phosphatase: Endpoint for in vitro toxicity tests , 1991, In Vitro Cellular & Developmental Biology - Animal.

[81]  M. Roddie,et al.  Phase I trial of temozolomide using an extended continuous oral schedule. , 1998, Cancer research.

[82]  M. Berger,et al.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.

[83]  M. Varma,et al.  Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport. , 2005, Molecular pharmaceutics.

[84]  M. Gerlinger,et al.  How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine , 2010, British Journal of Cancer.

[85]  S. Hilsenbeck,et al.  β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib , 2011, Breast Cancer Research.

[86]  I. Wodinsky,et al.  Studies on folic reductase. 3. The level of enzyme activity and response to methotrexate of transplantable mouse tumors. , 1965, Cancer research.

[87]  F. Zunino,et al.  Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to Taxol. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[88]  M. Clynes,et al.  Generation of lung cancer cell line variants by drug selection or cloning. , 2011, Methods in molecular biology.

[89]  J. Inazawa,et al.  Different drug sensitivity in two neuroblastoma cell lines established from the same patient before and after chemotherapy , 1991, International journal of cancer.

[90]  J. da Silva,et al.  Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. , 1985, Cancer research.

[91]  M. Gottesman,et al.  Changes in biophysical parameters of plasma membranes influence cisplatin resistance of sensitive and resistant epidermal carcinoma cells. , 2004, Experimental cell research.

[92]  M. Clynes,et al.  Comparison of 5 microplate colorimetric assays forin vitro cytotoxicity testing and cell proliferation assays , 2004, Cytotechnology.

[93]  J. Trent,et al.  Comparative properties of five human ovarian adenocarcinoma cell lines. , 1985, Cancer research.

[94]  M. Gönen,et al.  Evolutionary pathways in BRCA1-associated breast tumors. , 2012, Cancer discovery.

[95]  P. Fisher,et al.  Lapatinib Resistance in HCT116 Cells Is Mediated by Elevated MCL-1 Expression and Decreased BAK Activation and Not by ERBB Receptor Kinase Mutation , 2008, Molecular Pharmacology.

[96]  J. Schellens,et al.  Quantitative Effect of Gender, Age, Liver Function, and Body Size on the Population Pharmacokinetics of Paclitaxel in Patients with Solid Tumors , 2006, Clinical Cancer Research.

[97]  J. Verweij,et al.  Abrogated energy-dependent uptake of cisplatin in a cisplatin-resistant subline of the human ovarian cancer cell line IGROV-1 , 1997, Cancer Chemotherapy and Pharmacology.